Skip to main content
. Author manuscript; available in PMC: 2007 Feb 13.
Published in final edited form as: Nat Immunol. 2006 Oct 1;7(11):1209–1216. doi: 10.1038/ni1392

Figure 5.

Figure 5

Regulation of CCR5 expression on late apoptotic human PMNs. (a,b) Flow cytometry of CCR5 surface expression (a) and apoptotic phenotype (b) of human PMNs incubated for 22 h with vehicle, zVAD-fmk or TNF. (c) Flow cytometry of CCR5 surface expression and apoptotic phenotype of human PMNs exposed for 22 h to vehicle, resolution-phase lipid mediators or TGF-β. RvE1-Me, resolvin E1–methyl ester; ATLa, aspirin-triggered lipoxin A4 analog; PD1-Me, PD1–methyl ester. *, P < 0.05, vehicle versus experimental treatment. Results are representative of three experiments (a,b) and the mean ± s.e.m. of three experiments (c).